Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -16.00 is 238% below its 5-year average of -4.74, near the low end of its 5-year range (-17.85–-1.65).
64.10% below its 12-month average of -9.75.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -4.57.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-16.00
EARNINGS PER SHARE (EPS) AVG TTM
-9.75
EARNINGS PER SHARE (EPS) AVG 3Y
-5.91
EARNINGS PER SHARE (EPS) AVG 5Y
-4.74
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-64.10%
CURRENT VS 3Y AVG
-170.84%
CURRENT VS 5Y AVG
-237.91%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Bolt Biotherapeutics, Inc.
Market Cap
$6.74M
Earnings Per Share (EPS)
-16.00
TTM Avg
-9.75
3Y Avg
-5.91
5Y Avg
-4.74
Market Cap
$6.61M
Earnings Per Share (EPS)
-1.26
TTM Avg
-1.73
3Y Avg
-1.08
5Y Avg
-0.87
Market Cap
$6.88M
Earnings Per Share (EPS)
-1.31
TTM Avg
-1.19
3Y Avg
-1.26
5Y Avg
-5.87
Market Cap
$6.60M
Earnings Per Share (EPS)
-2.52
TTM Avg
-4.28
3Y Avg
-38.17
5Y Avg
-84.63
Market Cap
$6.60M
Earnings Per Share (EPS)
-7.60
TTM Avg
-3746.91
3Y Avg
-66167.96
5Y Avg
-82548.30
Market Cap
$6.58M
Earnings Per Share (EPS)
-16.46
TTM Avg
-132.36
3Y Avg
-129.45
5Y Avg
-404.68
Market Cap
$7.04M
Earnings Per Share (EPS)
-81.82
TTM Avg
-336.50
3Y Avg
-753.63
5Y Avg
-537.05
Market Cap
$7.07M
Earnings Per Share (EPS)
-7.38
TTM Avg
-1.62
3Y Avg
-0.82
5Y Avg
-0.82
Market Cap
$7.12M
Earnings Per Share (EPS)
-10.16
TTM Avg
-8.56
3Y Avg
-32.56
5Y Avg
-37.85
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.74M | -16.00 | -9.75 | -5.91 | -4.74 |
| Biomerica, Inc. (BMRA)vs › | $6.61M | -1.26 | -1.73 | -1.08 | -0.87 |
| Exicure, Inc. (XCUR)vs › | $6.88M | -1.31 | -1.19 | -1.26 | -5.87 |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | -2.52 | -4.28 | -38.17 | -84.63 |
| Aclarion, Inc. (ACON)vs › | $6.60M | -7.60 | -3746.91 | -66167.96 | -82548.30 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | -16.46 | -132.36 | -129.45 | -404.68 |
| KALA BIO, Inc. (KALA)vs › | $7.04M | -81.82 | -336.50 | -753.63 | -537.05 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | -7.38 | -1.62 | -0.82 | -0.82 |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | -10.16 | -8.56 | -32.56 | -37.85 |
| Longeveron Inc. (LGVN)vs › | $7.15M | -10.10 | -11.80 | -53.95 | -54.65 |
Trailing EPS (TTM)
$-16.00
Forward EPS (Est.)
$-17.89
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -17.85 |
| 2024-12-31 | -1.65 |
| 2023-12-31 | -1.83 |
| 2022-12-31 | -2.30 |
| 2021-12-31 | -2.79 |
| 2020-12-31 | -1.99 |
| 2019-12-31 | -3.75 |
| 2018-12-31 | -5.96 |
